Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Mitomycins

abstract

  • Fifty-one patients with advanced non-small cell lung carcinoma were treated with a combination of mitomycin C, vinblastine and cis-platin (MVP). Most cycles were given on an out-patient basis. Major side effects were leukopenia and peripheral neurotoxicity; one patient died of sepsis while leukopenic. In 44 evaluable patients the response rate was 50%, with one complete response. Overall median survival time was 280 days and median duration of responses was 232 days. A better performance status, disease limited to one hemithorax and no prior exposure to chemotherapy positively influenced the survival. MVP is an effective chemotherapy for non-small cell lung cancer and further experience with this combination is warranted.

publication date

  • January 1987

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2001818

Digital Object Identifier (DOI)

  • 10.1038/bjc.1987.227

PubMed ID

  • 2825750

Additional Document Info

start page

  • 475

end page

  • 8

volume

  • 56

number

  • 4